Anemia in Cardiovascular Disease: Marker of Disease Severity or Disease-modifying Therapeutic Target?

Goel, Harsh; Hirsch, Joshua R; Deswal, Anita; Hassan, Saamir A

Goel, Harsh; Hirsch, Joshua R; Deswal, Anita; Hassan, Saamir A.

Affiliation

Goel H; Department of Internal Medicine, The University of Texas Health Science Center, Houston, TX, USA.
Hirsch JR; Division of Internal Medicine, Baylor College of Medicine, Houston, TX, USA.
Deswal A; Department of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Hassan SA; Department of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. sahassan1@mdanderson.org.

Curr Atheroscler Rep ; 23(10): 61, 2021 08 10.

Article in En | MEDLINE | ID: mdl-34374878

Subject(s)

Anemia; Cardiovascular Diseases; Erythropoietin; Anemia/diagnosis; Anemia/drug therapy; Cardiovascular Diseases/epidemiology; Humans; Quality of Life; Severity of Illness Index

Key words

Anemia; Erythropoiesis-stimulating agents; Heart disease; Iron supplements; Red blood cell transfusions

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Cardiovascular Diseases / Erythropoietin / Anemia Type of study: Diagnostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Curr Atheroscler Rep Year: 2021 Document type: Article

Fulltext

XML

PubMed Links

Search on Google